HER2-positive Breast Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 32 expanded access programs, clinical trials, and compassionate use pathways listed for HER2-positive Breast Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with her2-positive breast cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 14 programs are currently active or recruiting, with the remaining 18 in other lifecycle stages. Sponsors actively running programs in this area include Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Hoffmann-La Roche, Memorial Sloan Kettering Cancer Center, Seagen, a wholly owned subsidiary of Pfizer, and others.
By recruiting status
Snapshot of where every HER2-positive Breast Cancer program currently sits in its lifecycle.
- Active / Recruiting14
- Inactive18
Top sponsors
Organisations running the most HER2-positive Breast Cancer programs in the directory.
- Dana-Farber Cancer Institute5 programs
- H. Lee Moffitt Cancer Center and Research Institute3 programs
- Hoffmann-La Roche2 programs
- Memorial Sloan Kettering Cancer Center2 programs
- Seagen, a wholly owned subsidiary of Pfizer2 programs
- Baylor Breast Care Center1 program
- City of Hope Medical Center1 program
- Filipa Lynce, MD1 program
- Fox Chase Cancer Center1 program
- Genentech, Inc.1 program
HER2-positive Breast Cancer programs (32)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 1 Study of ZN-A-1041 for HER2-Positive Advanced Solid Tumors — Hoffmann-La Roche
- Phase 2 Study of Zanidatamab and Chemotherapy for HER2-positive Breast Cancer Before Surgery — Jazz Pharmaceuticals
- Study on Surgery and Radiation Therapy for People with Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Tucatinib or Placebo with Trastuzumab and Pertuzumab for Advanced HER2+ Breast Cancer — Seagen, a wholly owned subsidiary of Pfizer
- Study on Tucatinib vs. Placebo with T-DM1 for Advanced or Metastatic HER2+ Breast Cancer — Seagen, a wholly owned subsidiary of Pfizer
- Study on Atezolizumab with Paclitaxel, Trastuzumab, and Pertuzumab for Patients with Advanced HER-2 Positive Breast Cancer — Fox Chase Cancer Center
- HERizon-Breast: Personalized Treatment Study for Long-Term Remission in HER2+ Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Margetuximab or Trastuzumab for Stage II-III HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
- Study on Neoadjuvant HER2-Targeted Therapy and Immunotherapy with Pembrolizumab for HER2-Positive Breast Cancer — University of Texas Southwestern Medical Center
- PHESGO Maintenance After Initial T-DXd Treatment for HER2+ Advanced Breast Cancer — MedSIR
- Study Comparing RO7771950 and Tucatinib with Trastuzumab and Capecitabine for Advanced HER2-Positive Breast Cancer — Hoffmann-La Roche
- The SAPPHO Study: Testing a New Treatment Plan for HER2+ Metastatic Breast Cancer — Dana-Farber Cancer Institute
- Trial of Pre-operative Neratinib and Hormone Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers — Ruth O'Regan
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Phase II Study of Hormone Therapy, Pertuzumab, and Trastuzumab for Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
- An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic — Genentech, Inc.
- Study on Anti-HER2 Therapy for Nigerian Women with HER2+ Breast Cancer Before and After Surgery — University of Chicago
- ATEMPT 2.0: Comparing Two Treatments After Surgery for HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
- Study on Biomarker Optimization of Pre-Surgery Therapy in Breast Cancer — University of Illinois at Chicago
- Study on How Tumor Shrinkage Before Surgery Relates to Remaining Cancer in Early Breast Cancer Patients — Baylor Breast Care Center
- I-SPY Trial: New and Personalized Treatments for Breast Cancer Before Surgery — QuantumLeap Healthcare Collaborative
- Margetuximab Access Program for Patients with HER2+ Breast Cancer — TerSera Therapeutics LLC
- Study on Non-Surgical Treatment Approach for Managing Breast Cancer — Ohio State University Comprehensive Cancer Center
- Study on Pertuzumab, Trastuzumab, and Paclitaxel for Treating HER2-Positive Advanced Breast Cancer — City of Hope Medical Center
- Study on Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab for HER2+ Breast Cancer Spread to the Brain and Spinal Fluid — H. Lee Moffitt Cancer Center and Research Institute
- Study on Stereotactic Brain Radiation with or without AGuIX Gadolinium-Based Nanoparticles for Brain Metastases — Dana-Farber Cancer Institute
- Study on HER2 Directed Dendritic Cell Vaccine with Weekly Paclitaxel, Trastuzumab, and Pertuzumab — H. Lee Moffitt Cancer Center and Research Institute
- Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer — NRG Oncology
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on Tucatinib with Capecitabine and Trastuzumab for Patients with Advanced HER2+ Breast Cancer — Seagen Inc.
- Study on TDXD and Durvalumab for HER2 Positive or Low Inflammatory Breast Cancer — Filipa Lynce, MD
- Study on TVB-2640 and Trastuzumab with Paclitaxel or Hormone Therapy for Treating HER2 Positive Metastatic Breast Cancer — Mayo Clinic
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as HER2-positive Breast Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.